

## BIBLIOGRAFIA

---

- AHMED, S.N. - Epilepsy seizures and epilepsy. **Epilepsia** 46 (2005) 1700-1701.
- ALBERTIONI, F. [et al.] - Simultaneous quantitation of methotrexate and its two main metabolites in biological fluids by a novel solid-phase extraction procedure using high-performance liquid chromatography. **J. Cromatogr. B** 665 (1995) 163-170.
- ALMEIDA, A.M. [et al.] - Kinetic profile of carbamazepine in an adult Portuguese outpatient population. **J. Clin. Pharm. Ther.** 22 (1998) 315-321.
- ALONSO GONZALEZ, A.C. [et al.] - Contribution of serum level monitoring in the individualization of carbamazepine dosage regimens. **Int. J. Clin. Pharmacol. Ther. Toxicol.** 26 (1988) 409-412.
- ALSAADI, T.M. [et al.] - Video-EEG telemetry can be a crucial tool for neurologists experienced in epilepsy when diagnosing seizure disorders. **Seizure** 13 (2004) 32-34.
- ANALYTICAL METHODS COMMITTEE - Uses (proper and improper) of correlation coefficients. **Analyst** 113 (1988) 1469-1471.
- ANDERSON, G.D. [et al.] - Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine and phenytoin. **Epilepsy Res.** 49 (2002) 211-217.
- ANDERSON, G.D. [et al.] - Bidirectional interaction of valproate and lamotrigine in healthy subjects. **Clin. Pharmacol. Ther.** 60 (1996) 145-156.
- ANGELIS-STOFORIDIS, P. [et al.] - Determination of lamotrigine in human plasma by high-performance liquid chromatography. **J. Chromatogr. B** 727 (1999) 113-118.
- ARMIJO, J.A. [et al.] - Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. **Ther. Drug Monit.** 21 (1999) 182-190.
- BALDAUF, C.M. [et al.] - Surgical outcome in patients with refractory epilepsy associated to MRI-defined unilateral mesial temporal sclerosis. **Arq. Neuropsiquiatr.** 64 (2006) 363-368.
- BARBOSA, N.R. e MÍDIO, A.F. - Validated high-performance liquid chromatographic method for the determination of lamotrigine in human plasma. **J. Chromatogr. B** 741 (2000) 289-293.
- BARDI, A.H. - Reduction of antiepileptic drug dosage for monitoring epileptic seizures. **Acta Neurol. Scand.** 86 (1992) 466-469.
- BARRET, C. e RICHENS, A. - Epilepsy and pregnancy: report of an Epilepsy Research Foundation Workshop. **Epilepsy Res.** 52 (2003) 147-187.
- BARTOLI, A. [et al.] - The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. **Ther. Drug Monit.** 19 (1997a) 252-260.
- BARTOLI, A. [et al.] - A rapid and specific assay for the determination of lamotrigine in human plasma by normal-phase HPLC. **Ther. Drug Monit.** 19 (1997b) 100-107.

BATTINO, D. [et al.] - Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. **Ther. Drug Monit.** 19 (1997) 620-627.

BATTINO, D. [et al.] - Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. **Ther. Drug Monit.** 23 (2001) 217-222.

BATTINO, D. [et al.] - Clinical pharmacokinetics of antiepileptic drugs in paediatric patients: Part I. Phenobarbital, primidone, valproic acid, ethosuximide, mesuximide. **Clin. Pharmacokinet.** 29 (1995a) 257-286.

BATTINO, D. [et al.] - Clinical pharmacokinetics of antiepileptic drugs in paediatric patients: Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. **Clin. Pharmacokinet.** 29 (1995b) 341-369.

BAUMANN, K. e WATZIG, H. - Appropriate calibration functions for capillary electrophoresis: II. Heteroscedasticity and its consequences. **J. Chromatogr. A** 700 (1995) 9-20.

BAXTER, M.G. [et al.] - Some studies on the convulsant action of acid folic **Br. J. Pharmacol.** 48 (1973) 350P-351P.

BEGHI, E. [et al.] - Comment on epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). **Epilepsia** 46 (2005) 1698-1702.

BENBADIS, S.R. [et al.] - How many patients with psychogenic nonepileptic seizures also have epilepsy. **Neurol.** 57 (2001) 915-917.

BENEDETTI, M.S. - Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. **Fundam. Clin. Pharmacol.** 14 (2000) 301-319.

BENETELLO, P. [et al.] - Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures. **Eur. Neurol.** 48 (2002) 200-203.

BERAN, R.G. [et al.] - Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalized epilepsy. **Epilepsia** 39 (12) (1998) 1329-1333.

BERK, M. - Lamotrigine and the treatment of mania in bipolar disorder. **Eur. Neuropsychopharmacol.** 9 Suppl. 4 (1999) S119-S123.

BERNUS, I. [et al.] - Inhibition of phenobarbitone N-glucosidation by valproate. **Br. J. Clin. Pharmacol.** 38 (1994) 411-416.

BERNUS, I. [et al.] - Anticonvulsant therapy in aged patients. **Drugs Aging** 10 (1997) 278-289.

BERRY, D.J. [et al.] - Lack of effect of topiramate on lamotrigine concentrations. **Epilepsia** 43 (2002) 818-823.

BESAG, F.M. [et al.] - The role of blood-level monitoring in assessing toxicity. **Epilepsia** 39 (2) (1998) 131.

BESAG, F.M.C. [et al.] - Methsuximide lowers lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction. **Epilepsia** 41 (5) (2000) 624-627.

BIDDLECOMBE, R.A. [et al.] - Validation of a radioimmunoassay for the determination of human plasma concentrations of lamotrigine. **J. Pharma. Biom. Anal.** 8 (1990) 691-694.

- BIENENTREU, S.D. e KRONMÜLLER, K.T.H. - Increase in risperidone plasma level with lamotrigine. **Am. J. Psychiatry** 162 (2005) 811-812.
- BINNIE, C.D. e MIZRAHI, E.M. - The epilepsy monitoring unit. In ENGEL JR., J. e PEDLEY, T.A. Eds. *Epilepsy: a comprehensive textbook*. Philadelphia: Lippincott-Raven Publishers, 1997. p. 1011- 1019.
- BINNIE, C.D. e STEFAN, H. - Modern electroencephalography: its role in epilepsy management. **Clin. Neurophysiol.** 110 (1999) 1671-1697.
- BIRNBAUM, A.K. [et al.] - Rectal absorption of lamotrigine compressed tablets. **Epilepsia** 41 (2000) 850-853.
- BITON, V. [et al.] - Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. **Neurol.** 56 (2001) 172-177.
- BOAS, J. [et al.] - Controlled trial of lamotrigine (Lamictal®) for treatment-resistant partial seizures. **Acta Neurol. Scand.** 94 (1996) 247-252.
- BONANNI, E. [et al.] - Neurophysiological evaluation of vigilance in epileptic patients on monotherapy with lamotrigine. **Clin. Neurophysiol.** 112 (2001) 1018-1022.
- BOON, P. [et al.] - Long-term Video-EEG monitoring revisited. **Eur. Neurol.** 34 (suppl 1) (1994) 33-39.
- BOOTHE, D.M. - Anticonvulsants and other neurologic therapies in small animals. In BOOTHE, D.M. Eds. *Small animal clinical pharmacology and therapeutics*. Philadelphia: W.B. Saunders Company, 2001. p. 431-456.
- BOTTIGER, Y. [et al.] - Lamotrigine drug interactions in a TDM material. **Ther. Drug Monit.** 21 (1999) 171-174.
- BOURGEOIS, B.F.D. - Important pharmacokinetic properties of antiepileptic drugs. **Epilepsia** 36 (1995) S1-S7.
- BOURIN, M. [et al.] - Evidence for the activity of lamotrigine at 5-HT<sub>1A</sub> receptors in the mouse forced swimming test. **J. Psychiatry Neurosci.** 30 (2005) 275-282.
- BOWDEN, C.L. [et al.] - Lamotrigine in the treatment of bipolar depression. **Eur. Neuropsychopharmacol.** 9 Suppl. 4 (1999) S113-S117.
- BOYLAN, L.S. [et al.] - Psychiatric uses of antiepileptic treatments. **Epilepsy Behav.** 3 (2002) S54-S59.
- BRAGGIO, S. [et al.] - A strategy for validation of bioanalytical methods. **J. Pharm. Biomed. Anal.** 14 (1996) 375-388.
- BRESSOLLE, F. [et al.] - Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics. **J. Chromatogr. B** 686 (1996) 3-10.
- BRODIE, M.B. - Do we need any more new antiepileptic drugs? **Epilepsy Res.** 45 (2001) 3-6.
- BRODIE, M.J. - Lamotrigine. **Lancet** 339 (1992) 1397-1400.
- BRODIE, M.J. e DICHTER, M.A. - Drug therapy: Antiepileptic drugs. **N. Engl. J. Med.** 334 (1996) 168-175.

BRODIE, M.J. e FEELY, J. - Practical clinical pharmacology. Therapeutic drug monitoring and clinical trials. **B.M.J.** 296 (1988) 1110- 1114.

BRODIE, M.J. e FRENCH, J.A. - Management of epilepsy in adolescents and adults. **Lancet** 356 (2000) 323–329.

BRODIE, M.J. [et al.] - Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. **Epilepsy Res.** 37 (1999) 81-87.

BRODIE, M.J. [et al.] - Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. **Lancet** 345 (1995) 476-479.

BRUNBECH, L. e SABERS, A. - Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. **Drugs** 62 (2002) 593-604.

BUCHANAN, N. - Lamotrigine: Clinical experience in 93 patients with epilepsy. **Acta Neurol. Scand.** 92 (1995) 28-32.

BUGAMELLI, F. [et al.] - Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction. **Anal. Chim. Acta** 472 (2002) 1-10.

BUICK, A.R. [et al.] - Method validation in bioanalytical laboratory. **J. Pharm. Biom. Anal.** 8 (1990) 629-637.

BURNS, M.J. [et al.] - Analysis and interpretation of data from real-time PCR trace detection methods using quantitation of GM soya as a model system. **Anal. Bioanal. Chem.** 378 (2004) 1616-1623.

CAMPBELL, T.J. e WILLIAMS, K.M. - Therapeutic drug monitoring: antiarrhythmic drugs **Br. J. Clin. Pharmacol.** 46 (1998) 307-319.

CANDITO, M. [et al.] - Antiepileptic drugs: a case report in a pregnancy with a neural tube defect. **Pediatric Neurol.** 34 (2006) 323-324.

CANTELO, R. [et al.] - Excitability of the human epileptic cortex after chronic valproate: a reappraisal. **Brain Res.** 1099 (2006) 160-166.

CARDONE, M.J. [et al.] - Method validation revisited: a chemometric approach. **Pharm. Res.** 7 (1990) 154-160.

CASTEL-BRANCO, M.M. [et al.] - Lamotrigine analysis in blood and brain by high-performance liquid chromatography. **J. Chromatogr. B** 755 (2001) 119-127.

CASTEL-BRANCO, M.M. [et al.] - Neuropharmacokinetic characterization of lamotrigine after its acute administration to rats. **Methods Find. Exp. Clin. Pharmacol.** 27 (2005) 1-7.

CHAFFIN, J.J. e DAVIS, S.M. - Suspected lamotrigine-induced toxic epidermal necrolysis. **Ann. Pharmacother.** 31 (1997) 720-723.

CHAN, V. [et al.] - Population Pharmacokinetics of lamotrigine. **Ther. Drug Monit.** 23 (2001) 630-635.

CHASSOUX, F. [et al.] - Metabolic changes and electro-clinical patterns in mesio-temporal lobe epilepsy: a correlative study. **Brain** 127 (2004) 164-174.

- CHEN, C. - Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children. **Br. J. Clin. Pharmacol.** 50 (2000) 135-145.
- CHEN, C. [et al.] - Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. **Pharmacother.** 19 (1999) 437-441.
- CHEN, C. [et al.] - Population pharmacokinetics of add-on lamotrigine in pediatric patients. **Ann. Neurol.** 42 (1997a) 508.
- CHEN, C. [et al.] - The effects of lamotrigine on the pharmacokinetics of lithium. **Br. J. Clin. Pharmacol.** 50 (2000) 193-195.
- CHEN, R. [et al.] - Effects of phenytoin on cortical excitability in humans. **Neurol.** 49 (1997b) 881-883.
- CHENG, C.L. [et al.] - Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. **J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.** 817 (2005) 199-206.
- CHIU, S.L. e HUSKEY, S.W. - Species differences in N-glucuronidation. **Drug Metab. Dispos.** 26 (1998) 838-847.
- CHOLLET, D.F. - Determination of antiepileptic drugs in biological material. **J. Chromatogr. B** 767 (2002) 191-233.
- CHONG, E. e DUPUIS, L.L. - Therapeutic drug monitoring of lamotrigine. **Ann. Pharmacother.** 36 (2002) 917-920.
- CHOONARA, I.A. e RANE, A. - Therapeutic drug monitoring of anticonvulsants: state of the art. **Clin. Pharmacokinet.** 18 (1990) 318-328.
- CHRISTENSEN, J. [et al.] - Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. **Epilepsia** 48 (2007) 484-489.
- CIANCHETTI, C. [et al.] - Low-dose lamotrigine in West syndrome. **Epilepsy Res.** 51 (2002) 199-200.
- CLEMENS, B. [et al.] - Lamotrigine decreases EEG synchronization in a use-dependent manner in patients with idiopathic generalized epilepsy. **Clin. Neurophysiol.** 118 (2007) 910-917.
- COCIGLIO, M. [et al.] - Performance analysis of a reversed-phase liquid chromatographic assay of lamotrigine in plasma using solvent-demixing extraction. **J. Chromatogr.** 572 (1991) 269-276.
- COHEN, A.F. [et al.] - Lamotrigine, a new anticonvulsant: pharmacokinetics in normal man. **Clin. Pharmacol. Ther.** 42 (1987) 535-541.
- COLUCCI, R. [et al.] - Effect of felbamate on the pharmacokinetics of lamotrigine. **J. Clin. Pharmacol.** 36 (1996) 634-638.
- COMMISSION ON ANTIEPILEPTIC DRUGS - Guidelines for therapeutic monitoring on antiepileptic drugs. **Epilepsia** 34 (1993) 585-587.
- COMMISSION ON CLASSIFICATION AND TERMINOLOGY OF THE ILAE - Proposal for revised clinical and electroencephalographic classification of epileptic seizures. **Epilepsia** 22 (1981) 248-501.
- COMMISSION ON CLASSIFICATION AND TERMINOLOGY OF THE ILAE - Proposal for revised classification of epilepsies and epileptic syndromes. **Epilepsia** 30 (1989) 389-399.

CONTIN, M. [et al.] - Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. **J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.** 828 (2005) 113-117.

COOPER, J.D.H. [et al.] - Simultaneous determination of lamotrigine and its glucuronide and methylated metabolites in human plasma by automated sequential trace enrichment of dialysates and gradient high-performance liquid chromatography. **J. Chromatogr. B** 702 (1997) 227-233.

CRAMER, J.A. [et al.] - Quality of life improvement with conversion to lamotrigine monotherapy. **Epilepsy Behav.** 5 (2004) 224-230.

CROCI, D. [et al.] - New high-performance liquid chromatographic method for plasma/serum analysis of lamotrigine. **Ther. Drug Monit.** 23 (2001) 665-668.

CUNNINGHAM, M.O. e JONES, R.S.G. - The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. **Neuropharmacol.** 39 (1999) 2139-2146.

DADGAR, D. [et al.] - Application issues in bioanalytical method validation, sample analysis and data reporting. **J. Pharm. Biomed. Anal.** 13 (1995) 89-97.

DALLAS, S. [et al.] - Multidrug resistance-associated proteins: expression and function in the central nervous system. **Pharmacol. Rev.** 58 (2006) 140-161.

DANIEL, W.W. (1987). *Biostatistics: a foundation for analysis in the health sciences*. Singapore, John Wiley & Sons. 4th ed. p. 367-377.

DAVIS, G. [et al.] - Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. **Drugs** 47 (1994) 332-372.

DECKERS, C.L.P. [et al.] - Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. **Epilepsia** 41 (2000) 1364-1374.

DECKERS, C.L.P. [et al.] - Current limitations of antiepileptic drug therapy: a conference review. **Epilepsy Res.** 53 (2003) 1-17.

DECRETO-LEI nº 45/2005. "D. R. Série A" 38 (05-02-23) 1625.

DEEKEN, J.F. e LÖSCHER, W. - The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. **Clin. Cancer Res.** 13 (2007) 1663-1674.

DELLA PASCHOA, O.E. [et al.] - Pharmacokinetic-pharmacodynamic correlation of lamotrigine, flunarizine, loreclezole, CGP40116 and CGP39551 in the cortical stimulation model. **Epilepsy Res.** 40 (2000) 41-52.

DEPOT, M. [et al.] - Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. **Clin. Pharmacol. Ther.** 48 (1990) 346-355.

DEVULDER, J. e LAAT, M. - Lamotrigine in the treatment of chronic refractory neuropathic pain. **J. Pain Symptom manage.** 19 (2000) 398-403.

DOIG, M.V. e CLARE, R.A. - Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine. **J. Chromatogr.** 554 (1991) 181-189.

DOOSE, D.R. [et al.] - Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. **Epilepsia** 44 (2003) 917-922.

DRANE, D.L. e MEADOR, K.J. - Cognitive and behavioral effects of antiepileptic drugs. **Epilepsy Behav.** 3 (2002) S49-S53.

DUCHOWNY, M. [et al.] - Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. **J. Child Neurol.** 17 (2002) 278-285.

DUCHOWNY, M. [et al.] - A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. **Neurol.** 53 (1999) 1724-1731.

DUMORTIER, G. [et al.] - Concomitant HPLC method for determination of lamotrigine, carbamazepine, and 10,11-carbamazepine epoxide in plasma using dual UV 240-220 nm wavelength detection. **J. Liq. Chrom. & Rel. Technol.** 24 (2001) 3171-3180.

DUNCAN, J.S. - Imaging and epilepsy. **Brain** 120 (1997) 339-377.

EADIE, M.J. - Therapeutic drug monitoring - antiepileptic drugs. **Br. J. Clin. Pharmacol.** 46 (1998) 185-193.

EBERT, U. [et al.] - Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. **Eur. J. Clin. Pharmacol.** 56 (2000) 299-304.

EDWARDS, K.R. [et al.] - Lamotrigine monotherapy improves depressive symptoms in epilepsy: A double-blind comparison with valproate. **Epilepsy Behav.** 2 (2001) 28-36.

EL DESOKY, E.S. e KANDIL, M.R. - Bayesian estimation of six different sets of carbamazepine pharmacokinetic parameters in Egyptian adult epileptic patients. **Pharmacol. Res.** 45 (2002) 113-118.

EMAMI, J. [et al.] - Development and validation of a new HPLC method for determination of lamotrigine and related compounds in tablet formulations. **J. Pharm. Biomed. Anal.** 40 (2006) 999-1005.

EMA - *Validation of Analytical Methods: Definitions and terminology* (CPMP/ICH/381/95). The European Agency for the Evaluation of Medicinal Products. Human Medicines Evaluation Unit. London. 1995a.

EMA - *Validation of Analytical Methods: Methodology* (CPMP/ICH/281/95). The European Agency for the Evaluation of Medicinal Products. Human Medicines Evaluation Unit. London. 1995b.

EMA - *Validation of Analytical procedures: Definition and terminology* (CVMP/VICH/590/98). The European Agency for the Evaluation of Medicinal Products. Veterinary Medicines Evaluation Unit. London. 1998.

ENGEL, J. - Classifications of the International League Against Epilepsy: time for reappraisal. **Epilepsia** 39 (1998) 1014-1017.

ENGEL, J. - International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. **Epilepsia** 42 (2001) 796-803.

ENGEL, J. - ILAE classification of epilepsy syndromes. **Epilepsy Res.** 70 (2006) S5-S10.

ENGEL JR, J. e CRANDALL, P.H. - Falsely localizing ictal onsets with depth EEG telemetry during anticonvulsant withdrawal. **Epilepsia** 24 (1983) 344-355.

ENGEL JR, J. [et al.] - Basic mechanisms of human epilepsy. In ENGEL JR., J. e PEDLEY, T.A. Eds. *Epilepsy: a comprehensive textbook*. Philadelphia: Lippincott-Raven Publishers, 1997. p. 499-512.

ENGEL JR, J. e PEDLEY, T.A. - Introduction: what is epilepsy? In ENGEL JR., J. e PEDLEY, T.A. Eds. *Epilepsy: a comprehensive textbook*. Philadelphia: Lippincott-Raven Publishers, 1997. p. 1-7.

ENGLE, P.M. e HECK, A.M. - Lamotrigine for the treatment of bipolar disorder. **Ann. Pharmacother.** 34 (2000) 258-262.

ERIKSSON, A. e BOREUS, L.O. - No increase in carbamazepine-10,11-epoxide during addition of lamotrigine treatment in children. **Ther. Drug Monit.** 19 (1997) 499-501.

ERIKSSON, A. [et al.] - Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. **Epilepsia** 37 (8) (1996) 769-773.

ESTEVEZ, A. e GARRET, C. - Antiepiléticos In OSSWALD, W. e GUIMARÃES, S. Eds. *Terapêutica Medicamentosa e suas bases farmacológicas*. Porto: Porto Editora, 2002. p. 222-232.

ETHELL, B.T. [et al.] - the effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. **Biochem. Pharmacol.** 65 (2003) 1441-1449.

ETTINGER, A.B. [et al.] - Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. **Epilepsia** 39 (1998) 874-877.

EURACHEM GUIDE - *The fitness for purpose of analytical methods: a laboratory guide to method validation and related topics*. Laboratory of the Government Chemist. Teddington. 1998.

EURACHEM/CITAC - *Eurachem/CITAC Guide CG 4 - Quantifying uncertainty in analytical measurement*. Laboratory of the Government Chemist. London. 2000.

EUROPEAN COMMISSION - EC regulation 49/2000/EC. 2000.

EUROPEAN COMMISSION - Notice to applicants and note for guidance: Establishment of maximum residue limits (MRLs) for residues of veterinary medicinal products in foodstuffs of animal origin. The Rules Governing Medicinal Products in the European Community. VOLUME 8. Brussels. 2003.

FADUL, C.E. [et al.] - Agranulocytosis associated with lamotrigine in a patient with low grade glioma. **Epilepsia** 43 (2002) 199-200.

FALCÃO, A.C. [et al.] - Predictive capacity of carbamazepine pharmacokinetic parameters in a Portuguese outpatient population. **Ther. Drug Monit.** 21 (1999) 224-230.

FAUGHT, E. - Epidemiology and drug treatment of epilepsy in elderly people. **Drugs Aging** 15 (1999) 255-269.

FAUGHT, E. [et al.] - Adding lamotrigine to valproate: incidence of rash and other adverse effects. **Epilepsia** 40 (1999) 1135-1140.

FAYAD, M. [et al.] - Potential hepatotoxicity of lamotrigine. **Pediatric Neurol.** 22 (2000) 49-52.

FAZIO, A. [et al.] - A liquid chromatography assay using a high-speed column for the determination of lamotrigine, a new antiepileptic drug, in human plasma. **Ther. Drug Monit.** 14 (1992) 509-512.

FILLASTRE, J.P. [et al.] - Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. **Drugs Exptl. Clin. Res.** 19 (1993) 25-32.



FISHER, R.S. - Epilepsy from the patient's perspective: review of results of a community-based survey. **Epilepsy Behav.** 1 (2000) S9-S14.

FISHER, R.S. [et al.] - Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). **Epilepsia** 46 (2005a) 470-472.

FISHER, R.S. [et al.] - Response: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). **Epilepsia** 46 (2005b) 1701-1702.

FITTON, A. e GOA, K.L. - Lamotrigine: an update of its pharmacology and therapeutic use. **Drugs** 50 (1995) 691-713.

FLEISHER, W. [et al.] - Comparative study of trauma-related phenomena in subjects with pseudoseizures and subjects with epilepsy. **Am. J. Psychiatry** 159 (2002) 660-663.

FORSGREN, L. [et al.] - The epidemiology of epilepsy in Europe - a systematic review. **Eur. J. Neurol.** 12 (2005) 245-253.

FORSBLAD, E. [et al.] - Liquid chromatographic determination of plasma lamotrigine in pediatric samples. **J. Pharm. Biomed. Anal.** 14 (1996) 755-758.

FRANK, L.M. [et al.] - Lamictal (lamotrigine) monotherapy for typical absence seizures in children. **Epilepsia** 40 (7) (1999) 973-979.

FRASER, A.D. [et al.] - Lamotrigine analysis in serum by high-performance liquid chromatography. **Ther. Drug Monit.** 17 (1995) 174-178.

FRÖSCHER, W. [et al.] - Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels. **Epileptic Disord.** 4 (2002) 46-56.

FURLAN, V. [et al.] - Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. **J. Pharmacol. Exp. Ther.** 289 (1999) 1169-1175.

GARDEN, J.S. [et al.] - Nonconstant variance regression techniques for calibration-curve-based analysis. **Anal. Chem.** 52 (1980) 2310-2315.

GARNETT, W.R. - Lamotrigine: pharmacokinetics. **J. Child Neurol.** 12 (1997) S10-S15.

GAULIER, J.M. [et al.] - Prediction of carbamazepine concentrations using a Bayesian program (PKS System, Abbott): a retrospective evaluation in an outpatient population. **J. Pharm. Pharmacol.** 49 (1997) 734-736.

GEORGE, S. [et al.] - Routine therapeutic monitoring of lamotrigine in epileptic patients using a simple and rapid high performance liquid chromatographic technique. **Ann. Clin. Biochem.** 32 (1995) 584-588.

GERHARD, U.J. [et al.] - "If Berger had Survived the Second World War - He Certainly would have been a Candidate for the Nobel Prize". Hans Berger and the Legend of the Nobel Prize. **Fortschr. Neurol. Psychiatr.** 73 (2005) 156-160.

GERMAN EPILEPSY MUSEUM (2008) - **Therapy**. Kork: 2008, actual. 18 Dez. 2004 [Consult. 30 Abril 2008]. Disponível em: <<http://www.epilepsiemuseum.de/english/therapie.html>>.

GIBBS, J.W. [et al.] - Anticonvulsant actions of lamotrigine on spontaneous thalamocortical rhythms. **Epilepsia** 43 (2002) 342-349.

GIDAL, B.E. [et al.] - Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. **Epilepsy Res.** 42 (2000) 23-31.

GIDAL, B.E. e GARNETT, W.R. - Perspective on lamotrigine. **Ann. Pharmacother.** 29 (1995) 191-192.

GIDAL, B.E. [et al.] - Lamotrigine pharmacokinetics in patients receiving felbamate. **Epilepsy Res.** 27 (1997a) 1-5.

GIDAL, B.E. [et al.] - Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. **Epilepsy Res.** 28 (1997b) 207-211.

GIDAL, B.E. [et al.] - Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetic: implications for conversion to lamotrigine monotherapy. **Epilepsy Res.** 57 (2003) 85-93.

GIDAL, B.E. e WELTY, T.E. - The concentration-effect with lamotrigine (LTG) (Letters to the editor) **Epilepsia** 38 (1997) 260.

GILLIAM, F. [et al.] - An active-control trial of lamotrigine monotherapy for partial seizures. **Neurol.** 51 (1998) 1018-1025.

GIORGI, L. [et al.] - The tolerability of lamotrigine in elderly patients with epilepsy. **Drugs Aging** 18 (2001) 621-630.

GOA, K.L. [et al.] - Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. **Drugs** 46 (1993) 152-176.

GOMEZ-ALONSO, J. [et al.] - On the definition of epileptic seizures and epilepsy. **Epilepsia** 46 (2005) 1699-1700.

GOTMAN, J. e KOFFLER, D.J. - Interictal spiking increases after seizures but does not after decreases in medication. **Electroencephalogr. Clin. Neurophysiol.** 72 (1989) 7-15.

GRAM, L. - Epileptic seizures and syndromes. **Lancet** 336 (1990) 8708-8710.

GRANT, S.M. e HEEL, R.C. - Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. **Drugs** 41 (1991) 889-926.

GRASELA, T.H. [et al.] - Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. **J. Clin. Pharmacol.** 39 (1999) 373-384.

GREEN, M.D. e TEPHY, T.R. - Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. **Drug Metab. Dispos.** 26 (1998) 860-867.

GREINER-SOSANKO, E. [et al.] - Simultaneous determination of lamotrigine, zonisamide, and carbamazepine in human plasma by high-performance liquid chromatography. **Biomed. Chromatogr.** 21 (2007) 225-228.

GROSS, A.S. - Best practice in therapeutic drug monitoring. **Br. J. Clin. Pharmacol.** 46 (1998) 95-99.

GRUNZE, H. [et al.] - Modulation of calcium and potassium currents by lamotrigine. **Neuropsychobiol.** 38 (1998) 131-138.

- GUBERMAN, A.H. [et al.] - Lamotrigine-associated rash: risk/benefit considerations in adults and children. **Epilepsia** 40 (1999) 985-991.
- GUÉNAULT, N. [et al.] - Increase in dihydroxycarbamazepine serum levels in patients co-medicated with oxcarbazepine and lamotrigine. **Eur. J. Clin. Pharmacol.** 59 (2003) 781-782.
- GUERRINI, R. [et al.] - The genetic and molecular basis of epilepsy. **Trends Mol. Med.** 9 (2003) 300-306.
- GUIDANCE FOR INDUSTRY - *Bioanalytical Methods Validation*. United States Food and Drug Administration. Washington D.C. 2001.
- HALLBACH, J. [et al.] - Determination of lamotrigine, carbamazepine and carbamazepine epoxide in human serum by gas chromatography mass spectrometry. **Eur. J. Clin. Chem. Clin. Biochem.** 35 (1997) 755-759.
- HARDEN, C. - Pregnancy effects on lamotrigine levels. **Epilepsy Curr.** 2 (2002) 183.
- HARDEN, C.L. [et al.] - The diagnostic significance of video-EEG monitoring findings on pseudoseizure patients differs between neurologists and psychiatrists. **Epilepsia** 44 (2003) 453-456.
- HART, A.P. [et al.] - Rapid cost-effective high-performance liquid chromatography (HPLC) assay of serum lamotrigine after liquid-liquid extraction and using HPLC conditions routinely used for analysis of barbiturates. **Ther. Drug Monit.** 19 (1997) 431-435.
- HARTMANN, C. [et al.] - An analysis of the Washington Conference Report on bioanalytical method validation. **J. Pharm. Biomed. Anal.** 12 (1994) 1337-1343.
- HARTMANN, C. [et al.] - Experience with chromatographic methods - Europe. In BLUME, H.H. e MIDHA, K.K. Eds. *Bioavailability, Bioequivalence and Pharmacokinetic Studies*. Stuttgart: Medpharm Scientific Publishers, 1995. p. 331-346.
- HARTMANN, C. [et al.] - Validation of bioanalytical chromatographic methods. **J. Pharm. Biomed. Anal.** 17 (1998) 193-218.
- HARTMANN, C. [et al.] - Detection of bias in method comparison by regression analysis. **Anal. Chim. Acta** 338 (1997) 19-40.
- HAUSER, W.A. - Incidence and prevalence. In ENGEL JR., J. e PEDLEY, T.A. Eds. *Epilepsy: a comprehensive textbook*. Philadelphia: Lippincott-Raven Publishers, 1997. p. 47-57.
- HAWES, E.M. - N<sup>+</sup>-glucuronidation, a common pathway in human metabolism of drugs with tertiary amine group. **Drug Metab. Dispos.** 26 (1998) 830-837.
- HENNESSY, M.J. e WILES, C.M. - Lamotrigine encephalopathy. **Lancet** 347 (1996) 974-975.
- HERMAN, E. - Lamotrigine: a depression mood stabilizer. **Eur. Neuropsychopharmacol.** 14 (2004) S89– S93.
- HERMANN, R. [et al.] - Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. **Eur. J. Clin. Pharmacol.** 58 (2003) 795-802.
- HILTON, E.J.R. [et al.] - The effect of antiepileptic drugs on visual performance. **Seizure** 13 (2004) 113–128.

HIRSCH, L.J. [et al.] - Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. **Neurol.** 63 (2004) 1022-1026.

HIRSCH, L.J. [et al.] - Predictors of lamotrigine-associated rash. **Epilepsia** 47 (2006) 318-322.

HOOPER, W. - Bioanalytical validation. A North American view. In BLUME, H.H. e MIDHA, K.K. Eds. *Bioavailability, Bioequivalence and Pharmacokinetic Studies*. Stuttgart: Medpharm Scientific Publishers, 1995. p. 399-403.

HSIAO, C. [et al.] - Extensive fixed drug eruption due to lamotrigine. **Br. J. Dermatol.** 144 (2001) 1262-1295.

HUANG, C.W. [et al.] - Inhibitory effect of lamotrigine on A-type potassium current in hippocampal neuron-derived H19-7 cells. **Epilepsia** 45 (2004) 729-736.

HURLEY, S.C. - Lamotrigine update and its use in mood disorders. **Ann. Pharmacother.** 36 (2002) 860-873.

HUSSEIN, Z. e POSNER, J. - Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. **Br. J. Clin. Pharmacol.** 43 (1997) 457-465.

IANNETTI, P. [et al.] - Lamotrigine hypersensitivity in childhood epilepsy. **Epilepsia** 39 (1998) 502-507.

INFARMED (2008) - **Medicamentos de uso Humano**. Lisboa: INFARMED, 2008, actual. 8 Maio 2008 [Consult. 8 Maio 2008]. Disponível em: <<http://www.infarmed.pt/infomed/pesquisa.php>>.

ISO 8466-1. 1990, Water quality - Calibration and evaluation of analytical methods and estimation of performance characteristics - Part 1: Statistical evaluation of the linear calibration function. ISO.

JAWAD, S. [et al.] - The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy. **Br. J. Clin. Pharmacol.** 22 (1986) 191-193.

JAWAD, S. [et al.] - Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. **Epilepsia** 30 (1989) 356-363.

JAWAD, S. [et al.] - Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. **Epilepsy Res.** 1 (1987) 194-201.

JENKE, D.R. - Chromatographic method validation: a review of current practices and procedures. I. General concepts and guidelines. **J. Liq. Chrom. & Rel. Technol.** 19 (1996a) 719-736.

JENKE, D.R. - Chromatographic method validation: a review of current practices and procedures. II. Guidelines for primary validation parameters. **J. Liq. Chrom. & Rel. Technol.** 19 (1996b) 737-757.

JENKE, D.R. - Chromatographic method validation: a review of current practices and procedures. III. Ruggedness, revalidation and system suitability. **J. Liq. Chrom. & Rel. Technol.** 19 (1996c) 1873-1891.

JOHANNESSEN, S.I. [et al.] - Therapeutic drug monitoring of the newer antiepileptic drugs. **Ther. Drug Monit.** 25 (2003) 347-363.

JOHANNESSEN, S.I. e TOMSON, T. - Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? **Clin. Pharmacokinet.** 45 (2006) 1061-1075.

JOHNSON, E.L. [et al.] - Biological sample preparation and data reduction concepts in pharmaceutical analysis. **J. Chromatogr. Sci.** 26 (1988) 372-379.

- JUERGENS, U. - Alkylamine/phosphoric acid as a universal buffer system for basic and acidic mobile phases in HPLC. **J. Liq. Chrom.** 11 (1988) 1925-1940.
- JÜRGENS, U. [et al.] - Systematic comparison of three basic methods of sample pretreatment for high-performance liquid chromatographic analysis of antiepileptic drugs using gas chromatography as a reference method. **Ther. Drug Monit.** 6 (1984) 334-343.
- KAMINOV, L. [et al.] - Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. **Epilepsy Behav.** 4 (2003) 659-666.
- KANNER, A.M. e FREY, M. - Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. **Neurol.** 55 (2000) 588-591.
- KARNES, H.T. e MARCH, C. - Calibration and validation of linearity in chromatographic biopharmaceutical analysis **J. Pharm. Biom. Anal.** 9 (1991) 911-918.
- KARNES, H.T. [et al.] - Validation of bioanalytical methods. **Pharm. Res.** 8 (1991) 421-426.
- KAUFMAN, K.R. e GERNER, R. - Lamotrigine toxicity secondary to sertraline. **Seizure** 7 (1998) 163-165.
- KECK JR., P.E. [et al.] - Advances in the pharmacologic treatment of bipolar depression. **Biol. Psychiatry** 53 (2003) 671-679.
- KILBAS, S. - Lamotrigine-induced leucopenia. **Epileptic Disord.** 8 (2006) 317.
- KILPATRICK, E.S. [et al.] - Concentration-effect and concentration-toxicity. Relations with lamotrigine: a prospective study. **Epilepsia** 37 (1996) 534-538.
- KIRKUP, L. e MULHOLLAND, M. - Comparison of linear and non-linear equations for univariate calibration. **J. Chromatogr. A** 1029 (2004) 1-11.
- KOSSEN, M. [et al.] - Elevated clozapine plasma level with lamotrigine. **Am. J. Psychiatry** 158 (2001) 1930.
- KOTAGAL, P. [et al.] - Paroxysmal nonepileptic events in children and adolescents. **Pediatrics** 110 (2002) 46-50.
- KRINGLE, R.O. - An assessment of the 4-6-20 rule for acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies. **Pharm. Res.** 11 (1994) 556-560.
- KUO, C. - A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na<sup>+</sup> channels. **Mol. Pharmacol.** 54 (1998) 712-721.
- KWAN, P. e BRODIE, M.J. - Early identification of refractory epilepsy. **N. Engl. J. Med.** 342 (2000) 314-319.
- KWAN, P. e BRODIE, M.J. - Effectiveness of first antiepileptic drug. **Epilepsia** 42 (2001) 1255-1260.
- KWAN, P. e BRODIE, M.J. - Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. **Epilepsia** 46 (2005) 224-235.
- KWAN, P. [et al.] - The mechanisms of action of commonly used antiepileptic drugs **Pharmacol. Ther.** 90 (2001) 21-34.

LAMUSUO, S. [et al.] - Comparison of [18F]FDG-PET, [99mTc]-HMPAO-SPECT, and [123I]-iomazenil-SPECT in localizing the epileptogenic cortex. **J. Neurol. Neurosurg. Psychiatry** 63: (1997) 743-748.

LANG, J.R. e BOLTON, S. - A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry - 1. Experimental considerations. **J. Pharm. Biomed. Anal.** 9 (1991a) 357-361.

LANG, J.R. e BOLTON, S. - A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry - 2. Statistical analysis. **J. Pharm. Biomed. Anal.** 9 (1991b) 435-442.

LARDIZABAL, D.V. [et al.] - Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring unit. **Epilepsia** 44 (2003) 536-539.

LARNER, A.J. e FARMER, S.F. - Neurology. Recent advances. **B.M.J.** 319 (1999) 362-366.

LAWDEN, M.C. [et al.] - Visual field defects associated with vigabatrin therapy. **J. Neurol. Neurosurg. Psychiatry** 67 (1999) 716-722.

LEACH, M.J. [et al.] - Neurochemical and behavioral aspects of lamotrigine. **Epilepsia** 32 (Suppl.2) (1991) S4-S8.

LEACH, M.J. [et al.] - Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. **Epilepsia** 27 (1986) 490-497.

LEE, D.S. [et al.] - Superiority of HMPAO ictal SPECT to ECD ictal SPECT in localizing the epileptogenic zone. **Epilepsia** 43 (2002) 263-269.

LEE, S.K. [et al.] - The clinical usefulness of ictal surface EEG in neocortical epilepsy. **Epilepsia** 41 (2000) 1450-1455.

LEGATT, A.D. e EBERSOLE, J.S. - Options for long-term monitoring. In ENGEL JR., J. e PEDLEY, T.A. Eds. *Epilepsy: a comprehensive textbook*. Philadelphia: Lippincott-Raven Publishers, 1997. p. 1011-1019.

LENSMEYER, G.L. [et al.] - Optimized high-performance-liquid chromatography method for determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide. **Ther. Drug Monit.** 19 (1997) 292-300.

LEVIE, R. - When, why, and how to use weighted least squares. **J. Chem. Educ.** 63 (1986) 10-15.

LEVY, R.H. [et al.] - Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. **Ther. Drug Monit.** 27 (2005) 193-198.

LINNET, K. - Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. **Hum. Psychopharmacol.** 17 (2002) 233-238.

LIPORACE, J. [et al.] - Concerns regarding lamotrigine and breast-feeding. **Epilepsy Behav.** 5 (2004) 102-105.

LOISEAU, P. [et al.] - A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. **Epilepsy Res.** 7 (1990) 136-145.

LOPES LIMA, J. - **Levantamento epidemiológico das epilepsias e dos síndromos epilépticos no Norte de Portugal** [dissertação]. Porto: Instituto de Ciências Biomédicas de Abel Salazar. Universidade do Porto. 1998.

LÖSCHER, W. - Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. **CNS Drugs** 16 (2002) 669-694.

LÖSCHER, W. - Mechanisms of drug resistance. **Epileptic Disord.** 7 (Suppl. 1) (2005) S3-S9.

LÖSCHER, W. e POTSCHKA, H. - Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. **J. Pharmacol. Exp. Ther.** 301 (2002) 7-14.

LUSZCZKI, J.J. [et al.] - Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. **Epilepsia** 44 (2003) 1003-1013.

MACDONALD, B. - The prognosis of epilepsy. **Seizure** 10 (2001) 347-358.

MACDONALD, B.K. [et al.] - The incidence and lifetime prevalence of neurological disorders in a prospective study in the UK. **Brain** 123 (2000) 665-676.

MACDONALD, R.L. e KELLY, K.M. - Mechanisms of action of currently prescribed and newly developed antiepileptic drugs **Epilepsia** 35 (suppl 4) (1994) S41-S50.

MAGDALOU, J. [et al.] - In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. **J. Pharmacol. Exp. Ther.** 260 (1992) 1166-1173.

MANGANOTTI, P. [et al.] - Cortical excitability in patients after loading doses of lamotrigine: a study with magnetic brain stimulation. **Epilepsia** 40 (1999) 316-321.

MARCELLIN, P. [et al.] - Influence of cirrhosis on lamotrigine pharmacokinetics **Br. J. Clin. Pharmacol.** 51 (2001) 410-414.

MARCIANI, M.G. e GOTMAN, J. - Effects of drug withdrawal on location of seizure onset. **Epilepsia** 27 (1986) 423-431.

MARCIANI, M.G. [et al.] - Patterns of seizure activation after withdrawal of antiepileptic medication. **Neurol.** 35 (1985) 1537-1543.

MARCIANI, M.G. [et al.] - Effect of lamotrigine on EEG paroxysmal abnormalities and background activity: a computerized analysis. **Br. J. Clin. Pharmacol.** 42 (1996) 621-627.

MARCIANI, M.G. [et al.] - Neurophysiologic and neuropsychologic profiles of lamotrigine in epilepsy. **Clin. Neuropharmacol.** 22 (1999) 159-163.

MARCIANI, M.G. [et al.] - Lamotrigine add-on therapy in focal epilepsy: electroencephalographic evaluation. **Clin. Neuropharmacol.** 21 (1998) 41-47.

MARKS, D.A. [et al.] - Clinical and electrographic effects of acute anticonvulsant withdrawal in epileptic patients. **Neurol.** 41 (1991) 508-512.

MATAR, K.M. [et al.] - Liquid chromatographic determination of six antiepileptic drugs and two metabolites in microsamples of human plasma. **Ther. Drug Monit.** 21 (1999) 559-566.

MATSUO, F. - Lamotrigine. **Epilepsia** 40 (suppl. 5) (1999) S30- S36.

MATSUO, F. [et al.] - Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. **Neurol.** 43 (1993) 2284-2291.

MATTSON, R.H. e GIDAL, B.E. - Fractures, epilepsy and antiepileptic drugs. **Epilepsy Behav.** 5 (2004) S36-S40.

MAY, T.W. [et al.] - Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with or without valproic acid co-medication: results on a retrospective study. **Ther. Drug Monit.** 21 (1999) 175-181.

MAY, T.W. [et al.] - Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. **Ther. Drug Monit.** 18 (1996) 523-531.

MCAULEY, J.W. e ANDERSON, G.D. - Treatment of epilepsy in women of reproductive age. **Clin. Pharmacokinet.** 48 (2002) 559-579.

MCCRUDDEN, E.A. e TETT, S.E. - Improved high-performance liquid chromatography determination of methotrexate and its major metabolite in plasma using a poly(styrene-divinylbenzene) column. **J. Chromatogr. B** 721 (1999) 87-92.

MEADOR, K.J. [et al.] - Differential cognitive and behavioral effects of carbamazepine and lamotrigine. **Neurol.** 56 (2001) 1177-1182.

MEHTA, A.C. - The validation criteria for analytical methods used in pharmacy practice research. **J. Clin. Pharm. Ther.** 14 (1989) 465-473.

MELDRUM, B.S. - Anatomy, physiology, and pathology of epilepsy. **Lancet** 336 (1990) 231-234.

MELDRUM, B.S. (1994). *Action of established and novel anticonvulsant drugs on the basic mechanisms of epilepsy*. International Conference for the Definition and Debate of Rational Polytherapy., Colorado, LEPPIK, I.E. Elsevier Science. 67-77.

MELDRUM, B.S. - Update on the mechanism of action of antiepileptic drugs. **Epilepsia** 37 (suppl 6) (1996) S4-S11.

MESSENHEIMER, J. - Efficacy and safety of lamotrigine in pediatric patients. **J. Child Neurol.** 17 (2002) 2S34-2S42.

MESSENHEIMER, J.A. - Lamotrigine. **Epilepsia** 36 (1995) S87-S94.

MESSENHEIMER, J.A. [et al.] - Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, crossover trial. **Epilepsia** 35 (1994) 113-121.

METZLER, C.M. [et al.] - A package of computer programs for pharmacokinetic modelling. **Biometrics** 30 (1974) 562-563.

MEYER, F.P. [et al.] - Lamotrigine concentrations in human serum, brain tissue, and tumor tissue. **Epilepsia** 40 (1) (1999) 68-73.

MIKATI, M.A. [et al.] - Efficacy, tolerability, and kinetics of lamotrigine in infants. **J. Pediatr.** 141 (2002) 31-35.

MIKATI, M.A. [et al.] - Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. **Clin. Neuropharmacol.** 12 (1989) 312-321.

MILLER, A.A. [et al.] - Lamotrigine In MELDRUM, B.L. e PORTER, R.J. Eds. *Current problems in epilepsy. New antiepileptic drugs*. London: John Libbey, 1986a. p. 165-177.



- MILLER, A.A. [et al.] - Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. **Epilepsia** 27 (1986b) 483-489.
- MILLER, J.C. e MILLER, J.N. - Basic statistical methods for analytical chemistry. Part I: Statistics of repeated measurements. A review. **Analyst** 113 (1988) 1351-1356.
- MILLER, J.N. - Basic statistical methods for analytical chemistry. Part 2: Calibration and regression methods. **Analyst** 116 (1991) 3-14.
- MINERS, J.O. [et al.] - Influence of sex and oral contraceptive steroids on paracetamol metabolism. **Br. J. Clin. Pharmacol.** 16 (1983) 503-509.
- MINERS, J.O. [et al.] - Drug glucuronidation in humans. **Pharmacol. Ther.** 51 (1991) 347-369.
- MINERS, J.O. [et al.] - Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. **Toxicology** 181-182 (2002) 453-456.
- MITCHELL, P.B. - Therapeutic drug monitoring of psychotropic medications. **Br. J. Clin. Pharmacol.** 49 (2000) 303-312.
- MORRELL, M.J. [et al.] - Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. **Epilepsy Res.** 54 (2003) 189-199.
- MORRIS, R.G. [et al.] - Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. **Br. J. Clin. Pharmacol.** 46 (1998) 547-551.
- MORRIS, R.G. [et al.] - Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? **Ther. Drug Monit.** 22 (2000) 656-660.
- MOTTE, J. [et al.] - Lamotrigine for generalized seizures associated with the Lennox-Gastaut Syndrome. **N. Eng. Med. J.** 337 (1997) 1807-1812.
- MULHOLLAND, M. e HIBBERT, D.B. - Linearity and limitations of the least squares calibration. **J. Chromatogr. A** 762 (1997) 73-82.
- MYLLYNEN, P.K. e PIENIMAKI, P.K. - Transplacental passage of lamotrigine in human placental perfusion system in vitro and in maternal and cord blood in vivo. **Eur. J. Clin. Pharmacol.** 58 (2003) 677-682.
- MYLONAKIS, E. [et al.] - Lamotrigine overdose presenting as anticonvulsant hypersensitivity syndrome. **Ann. Pharmacother.** 33 (1999) 557-559.
- NAGARAJA, N.V. [et al.] - Choosing the calibration model in assay validation. **J. Pharm. Biom. Anal.** 20 (1999) 433-438.
- NAISBITT, D.J. - Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. **Toxicology** 194 (2004) 179-196.
- NAISBITT, D.J. [et al.] - Characterization of drug-specific T-cells in lamotrigine hypersensitivity. **J. Allergy Clin. Immunol.** 111 (2003) 1393-1403.
- NEUFELD, M.Y. [et al.] - Comparison of the effects of vigabatrin, lamotrigine, and topiramate on quantitative EEGs in patients with epilepsy. **Clin. Neuropharmacol.** 22 (1999) 80-86.
- NORMANN, C. [et al.] - Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. **J. Clin. Psychiatry** 63 (2002) 337-344.

- NORONHA, A.L. [et al.] - Prevalence and pattern of epilepsy treatment in different socioeconomic classes in Brazil. **Epilepsia** 48 (2007) 880-885.
- NSOUR, W.M. [et al.] - Review on phytotherapy in epilepsy. **Seizure** 9 (2000) 96-107.
- OHMAN, I. [et al.] - Effects of pregnancy and contraception on lamotrigine disposition: New insights through analysis of lamotrigine metabolites. **Seizure** 17 (2008) 199-202.
- OHMAN, I. [et al.] - Lamotrigine in pregnancy: pharmacokinetics during delivery, in neonates, and during lactation. **Epilepsia** 41 (2000) 709-713.
- OLSON, D.M. - Treatment considerations: role of surgery. **Epilepsy Behav.** 3 (2002) S32-S40.
- ORTINSKI, P. e MEADOR, K.J. - Cognitive side effects of antiepileptic drugs. **Epilepsy Behav.** 5 (2004) S60-S65.
- PANAYIOTOPOULOS, C.P. [et al.] - Interaction of lamotrigine with sodium valproate. **Lancet** 341 (1993) 445.
- PAPADOYANNIS, I.N. [et al.] - Solid-phase extraction study and RP-HPLC analysis of lamotrigine in human biological fluids and in antiepileptic tablet formulations. **J. Liq. Chrom.** 18 (1995) 2593-2609.
- PATEMAN, J. - Standard curve In BLUME, H.H. e MIDHA, K.K. Eds. *Bioavailability, Bioequivalence and Pharmacokinetic Studies*. Stuttgart: Medpharm Scientific Publishers, 1995. p. 399-403.
- PATIL, K.M. e BODHANKAR, S.L. - High-performance thin-layer chromatographic determination of lamotrigine in serum. **J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.** 823 (2005a) 152-157.
- PATIL, K.M. e BODHANKAR, S.L. - Simultaneous determination of lamotrigine, phenobarbitone, carbamazepine and phenytoin in human serum by high-performance liquid chromatography. **J. Pharm. Biomed. Anal.** 39 (2005b) 181-186.
- PATSALOS, P.N. [et al.] - The importance of drug interactions in epilepsy therapy. **Epilepsia** 43 (2002) 365-385.
- PATSALOS, P.N. e PERUCCA, E. - Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. **Lancet Neurol.** 2 (2003a) 347-356.
- PATSALOS, P.N. e PERUCCA, E. - Clinically important drug interactions in epilepsy: interaction between antiepileptic drugs and other drugs. **Lancet Neurol.** 2 (2003b) 473-481.
- PATSALOS, P.N. [et al.] - Intracerebral microdialysis shows that vigabatrin does not exhibit ubiquitous brain extracellular distribution. **Seizure** 8 (1999) 372.
- PECK, A.W. - Clinical pharmacology of lamotrigine. **Epilepsia** 32 (1991) S9-S12.
- PERUCCA, E. - Is there a role for therapeutic drug monitoring of the new anticonvulsants? **Clin. Pharmacokinet.** 38 (2000) 191-204.
- PERUCCA, E. - Marked new antiepileptic drugs: are they better than old-generation agents? **Ther. Drug Monit.** 24 (2002) 74-80.
- PERUCCA, E. - Clinically relevant drug interactions with antiepileptic drugs. **Br. J. Clin. Pharmacol.** 61 (2006) 246-255.
- PETRENAITE, V. [et al.] - Individual changes in lamotrigine plasma concentrations during pregnancy. **Epilepsy Res.** 65 (2005) 185-188.

PIERELLI, F. [et al.] - Long-term EEG-video-audio monitoring: detection of partial epileptic seizures and psychogenic episodes by 24-hour record review. **Epilepsia** 30 (1989) 513-523.

PISANI, F. [et al.] - Interaction of lamotrigine with sodium valproate. **Lancet** 341 (1993) 1224.

PISANI, F. [et al.] - The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. **Epilepsia** 40 (1999) 1141-1146.

PLACIDI, F. [et al.] - Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy. **Acta Neurol. Scand.** 102 (2000) 81-86.

PORTER, R.J. e ROGAWSKI, M.A. - New antiepileptic drugs: from serendipity to rational discovery. **Epilepsia** 33 (1992) S1-S6.

POSNER, J. [et al.] - The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's Syndrome). **Br. J. Clin. Pharmacol.** 28 (1989) 117-120.

POSNER, J. [et al.] - Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers **J. Pharmaceut. Med.** 1 (1991) 121-128.

POTSCHKA, H. [et al.] - P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. **Neurosci. Lett.** 327 (2002) 173-176.

PRAKASH [et al.] - Lamotrigine in pregnancy: safety profile and the risk of malformations. **Singapore Med J.** 48 (2007) 880-883.

QUEIROZ, M.E. [et al.] - Determination of lamotrigine simultaneously with carbamazepine, carbamazepine epoxide, phenytoin, phenobarbital, and primidone in human plasma by SPME-GC-TSD. **J. Chromatogr. Sci.** 40 (2002) 219-223.

QUINONEZ, D. - Common applications of electrophysiology (EEG) in the past and today: the technologist's view. **Electroencephalogr. Clin. Neurophysiol.** 106 (1998) 108-112.

RAMACHANDRAN, S. [et al.] - Measurement of lamotrigine under conditions measuring phenobarbitone, phenytoin, and carbamazepine using reversed-phase high-performance liquid chromatography at dual wavelengths. **Ther. Drug Monit.** 16 (1994) 75-82.

RAMBECK, B. [et al.] - Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. **Epilepsia** 47 (2006) 681-694.

RAMBECK, B. [et al.] - Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. **Eur. J. Clin. Pharmacol.** 51 (1997) 481-484.

RAMBECK, B. [et al.] - Postmortem concentrations of phenobarbital, carbamazepine, and its metabolite carbamazepine-10,11-epoxide in different regions of the brain and in the serum: analysis of autoptic specimens from 51 epileptic patients. **Ther. Drug Monit.** 15 (1993) 91-98.

RAMBECK, B. [et al.] - Postmortem concentrations of phenytoin in different regions of the brain and in the serum: analysis of autoptic specimens from 24 epileptic patients. **Ther. Drug Monit.** 14 (1992) 27-35.

RAMBECK, B. [et al.] - Pharmacokinetic interactions of the new antiepileptic drugs. **Clin. Pharmacokinet.** 31 (1996) 309-323.

- RAMBECK, B. e WOLF, P. - Lamotrigine clinical pharmacokinetics. **Clin. Pharmacokinet.** 25 (1993) 433-443.
- REIJS, R. [et al.] - Mood effects of antiepileptic drugs. **Epilepsy Behav.** 5 (2004) S66-S76.
- REIMERS, A. [et al.] - Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. **Epilepsia** 46 (2005) 1414-1417.
- REIS, J. [et al.] - Topiramate selectively decreases intracortical excitability in human motor cortex. **Epilepsia** 43 (2002) 1149-1156.
- REMMELE, R.P. e SINZ, M.W. - A quaternary ammonium glucuronide is the major metabolite of lamotrigine in guinea pigs. **Drug Metab. Dispos.** 19 (1991) 630-636.
- REMY, S. e BECK, H. - Molecular and cellular mechanisms of pharmacoresistance in epilepsy. **Brain** 129 (2006) 18-35.
- REN, S. [et al.] - Determination of lamotrigine in biologic materials by a simple and rapid liquid chromatographic method. **Ther. Drug Monit.** 20 (1998) 209-214.
- REUTENS, D.C. [et al.] - Disabling tremor after lamotrigine with sodium valproate. **Lancet** 342 (1993) 185-186.
- RICHEMS, A. - Safety of lamotrigine. **Epilepsia** 35 (1994) S37-S40.
- RIED, S. [et al.] - From clinical observation to long-term monitoring: diagnostic developments in conservative epileptology. **Epilepsia** 41 (2000) S2- S9.
- RIVA, R. [et al.] - Pharmacokinetic interactions between antiepileptic drugs: Clinical considerations. **Clin. Pharmacokinet.** 31 (1996) 470-493.
- ROGAWSKI, M.A. - Does P-glicoprotein play a role in the pharmacoresistance to antiepileptic drugs? **Epilepsy Behav.** 3 (2002) 493-495.
- ROWLAND, A. [et al.] - In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. **Drug Metab. Dispos.** 34 (2006) 1055-1062.
- RYAN, M. e BAUMANN, R.J. - Use and monitoring of bromides in epilepsy treatment. **Pediatric Neurol.** 21 (1999) 523-528.
- SABERS, A. [et al.] - Lamotrigine plasma levels reduced by oral contraceptives. **Epilepsy Res.** 47 (2001) 151-154.
- SABERS, A. [et al.] - Epilepsy and pregnancy: lamotrigine as main drug used. **Acta Neurol. Scand.** 109 (2004) 9-13.
- SABERS, A. [et al.] - Oral contraceptives reduce lamotrigine plasma levels. **Neurol.** 61 (2003) 570-571.
- SADRAY, S. [et al.] - Non-linear heteroscedastic regression model for determination of methotrexate in human plasma by high-performance liquid chromatography. **J. Chromatogr. B** 787 (2003) 293-302.
- SAILSTAD, J.M. e FINDLAY, J.W.A. - Immunofluorometric assay for lamotrigine (Lamictal) in human plasma. **Ther. Drug Monit.** 13 (1991) 433-442.
- SALAS-PUIG, J. e GIL-NAGEL, A. - La clasificación de las crisis y síndromes epiléticos: nuevas propuestas. **Neurología** 19 (2004) 59-66.

SALLUSTIO, B. e MORRIS, R.G. - High-performance liquid chromatography quantification of plasma lamotrigine concentrations: application measuring trough concentrations in patients with epilepsy. **Ther. Drug Monit.** 19 (1997) 688-693.

SANTOYO, E. e VERMA, S.P. - Determination of lanthanides in synthetic standards by reversed-phase high-performance liquid chromatography with the aid of a weighted least-squares regression model: Estimation of method sensitivities and detection limits. **J. Chromatogr. A** 997 (2003) 171-182.

SCHACHTER, S.C. - Current evidence indicates that antiepileptic drugs are anti-ictal, not antiepileptic. **Epilepsy Res.** 50 (2002) 67-70.

SCHAPPEL, G.J. [et al.] - Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. **J. Neurol. Neurosurg. Psychiatry** 56 (1993) 448-453.

SCHAPPEL, G.J. [et al.] - Combination vigabatrin and lamotrigine therapy for intractable epilepsy. **Seizure** 5 (1996) 51-56.

SCHEUER, M.L. e PEDLEY, T.A. - Current concepts: The evaluation and treatment of seizures. **N. Engl. J. Med.** 22 (1990) 1468-1474.

SCHLUMBERGER, E. [et al.] - Lamotrigine in treatment of 120 children with epilepsy. **Epilepsia** 35 (2) (1994) 359-367.

SCOTT, C. [et al.] - Design of an intensive epilepsy monitoring unit. **Epilepsia** 41 (suppl. 5) (2000) S3- S8.

SCOTT, C.A. [et al.] - Presurgical evaluation of patients with epilepsy and normal MRI: role of scalp video-EEG telemetry. **J. Neurol. Neurosurg. Psychiatry** 66 (1999) 69-71.

SHAH, V.P. e MIDHA, K.K. - Analytical Methods Validation, Onwards from Arlington 1990. In BLUME, H.H. e MIDHA, K.K. Eds. *Bioavailability, Bioequivalence and Pharmacokinetic Studies*. Stuttgart: Medpharm Scientific Publishers, 1995. p. 321-324.

SHAH, V.P. [et al.] - Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. **Eur. J. Drug Metab. Pharmacokinet.** 16 (1991) 249-255.

SHAH, V.P. [et al.] - Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. **J. Pharm. Sci.** 81 (1992a) 309-312.

SHAH, V.P. [et al.] - Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. **Pharm. Res.** 9 (1992b) 588-592.

SHAH, V.P. [et al.] - Bioanalytical method validation - a revisit with a decade of progress. **Pharm. Res.** 17 (2000) 1551-1557.

SHARMA, C. [et al.] - Food reduces the bioavailability of lamotrigine. **Indian J. Med. Res.** 121 (2005) 659-664.

SHEINER, L.B. e BEAL, S.L. - Some suggestions for measuring predictive performance. **J. Pharmacokinet. Biopharm.** 9 (1981) 503-513.

SHERWIN, A.L. [et al.] - Correlation of anticonvulsant levels in human plasma and epileptogenic brain. **Trans. Am. Neurol Assoc.** 98 (1973) 199-203.

SHIAH, I. [et al.] - Effect of lamotrigine on plasma GABA levels in healthy humans. **Prog Neuropsychopharmacol. Biol. Psychiatry.** 27 (2003) 419-423.

SHIHABI, Z.K. e OLES, K.S. - Serum lamotrigine analysis by capillary electrophoresis. **J. Chromatogr. B** 683 (1996) 119-123.

SHORVON, S.D. - Epidemiology, classification, natural history, and genetics of epilepsy. **Lancet** 336 (1990) 93-96.

SHORVON, S.D. - The epidemiology and treatment of chronic and refractory epilepsy. **Epilepsia** 37 (1996) S1-S3.

SIDHU, J. [et al.] - Pharmacokinetics and tolerability of lamotrigine and olanzepine coadministered to healthy subjects. **Br. J. Clin. Pharmacol.** 61 (2006a) 420-426.

SIDHU, J. [et al.] - The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. **Br. J. Clin. Pharmacol.** 61 (2006b) 191-199.

SINZ, M.W. e REMMEL, R.P. - Analysis of lamotrigine and lamotrigine 2-N-glucuronide in guinea pig blood and urine by reversed-phase ion-pairing liquid chromatography. **J. Chromatogr.** 571 (1991a) 217-230.

SINZ, M.W. e REMMEL, R.P. - Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine. **Drug Metab. Dispos.** 19 (1991b) 149-153.

SISODIYA, S.M. [et al.] - Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. **Brain** 125 (2002) 22-31.

SMITH, D. [et al.] - Outcomes of add-on treatment with lamotrigine in partial epilepsy. **Epilepsia** 34 (1993) 312-322.

SO, E.L. e FISCH, B.J. - Drug withdrawal and other activating techniques. In ENGEL JR., J. e PEDLEY, T.A. Eds. *Epilepsy: a comprehensive textbook*. Philadelphia: Lippincott-Raven Publishers, 1997. p. 1021-1027.

SO, N. e GOTMAN, J. - Changes in seizure activity following anticonvulsant drug withdrawal. **Neurol.** 40 (1990) 407-413.

SPARREBOOM, A. [et al.] - Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel. **J. Chromatogr. B** 735 (1999) 111-119.

SPECHT, U. [et al.] - Postictal serum levels of antiepileptic drugs for detection of noncompliance. **Epilepsy Behav.** 4 (2003) 487-495.

SPINA, E. [et al.] - Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. **Ther. Drug Monit.** 28 (2006) 599-602.

SPINA, E. e LEON, J. - Metabolic drug interactions with newer antipsychotics: a comparative review. **Basic Clin. Pharmacol. Toxicol.** 100 (2007) 4-22.

SPINA, E. e PERUGI, G. - Antiepileptic drugs: indications other than epilepsy. **Epileptic Disord.** 6 (2004) 57-75.

STEFAN, H. [et al.] - Magnetic Resonance Spectroscopy and histopathological findings in temporal lobe epilepsy. **Epilepsia** 42 (2001) 41-46.

STEFAN, H. [et al.] - A new approach in the anti-epileptic drug evaluation. **Eur. J. Neurol.** 11 (2004) 467-473.

STEFANI, A. [et al.] - Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. **Exp. Neurol.** 147 (1997) 115-122.

STEFANI, A. [et al.] - Lamotrigine inhibits  $Ca^{2+}$  currents in cortical neurons: functional implications. **Eur. J. Pharmacol.** 307 (1996) 113-116.

STEIJNS, L.S.W. [et al.] - Evaluation of fluorescence polarization assays for measuring valproic acid, phenytoin, carbamazepine and phenobarbital in serum. **Ther. Drug Monit.** 24 (2002) 432-435.

STEINER, T.J. [et al.] - Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. **Epilepsia** 40 (1999) 601-607.

STEPHEN, L.J. e BRODIE, M.J. - Epilepsy in elderly people. **Lancet** 355 (2000) 1441-1446.

SWARTJES, J.M. e VAN GEIJN, H.P. - Pregnancy and epilepsy. **Eur. J. Obstet. Gynecol. Reprod. Biol.** 79 (1998) 3-11.

SWICK, C.T. [et al.] - Seizure occurrence during long-term monitoring. **Epilepsia** 37 (1996) 927-930.

SWINYARD, E.A. e GOODMAN, L.S. - Introduction. In WOODBURY, D.M.; PENRY, J.K. e SCHMIDT, R.P. Eds. *Antiepileptic Drugs*. New York: Raven Press, 1972. p. 1-5.

SZABO, G.K. [et al.] - Alternatives to least squares linear regression analysis for computation of standard curves for quantification by high performance liquid chromatography: applications to clinical pharmacology. **J. Clin. Pharmacol.** 34 (1994) 242-249.

TERGAU, F. [et al.] - Relationship between lamotrigine oral dose, serum level and its inhibitory effect on CNS: insights from transcranial magnetic stimulation. **Epilepsy Res.** 56 (2003) 67-77.

THEIS, J.G.W. [et al.] - Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. **Neuropsychopharmacol.** 30 (2005) 2269-2274.

THEURILLAT, R. [et al.] - Therapeutic drug monitoring of lamotrigine using capillary electroforesis. Evaluation of assay performance and quality assurance over a 4-year period in the routine arena. **J. Chromatogr. A** 979 (2002) 353-368.

THOMPSON, M. - Variation of precision with concentration in an analytical system. **Analyst** 113 (1988) 1579-1587.

THOMSON, A.H. e BRODIE, M.J. - Pharmacokinetic optimization of anticonvulsant therapy. **Clin. Pharmacokinet.** 23 (1992) 216-230.

THORMANN, W. [et al.] - Therapeutic drug monitoring of antiepileptics by capillary electroforesis: characterization of assays via analysis of quality control sera containing 14 analytes. **J. Chromatogr. A** 924 (2001) 429-437.

TIMM, U. [et al.] - A new approach for dealing with the stability of drugs in biological fluids. **J. Pharm. Sci.** 74 (1985) 972-977.

TOMSON, T. e BATTINO, D. - Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. **Clin. Pharmacokinet.** 46 (2007) 209-219.

TOMSON, T. e JOHANNESSEN, S.I. - Therapeutic monitoring of the new antiepileptic drugs. **Eur. J. Clin. Pharmacol.** 55 (2000) 697-705.

TOMSON, T. [et al.] - Lamotrigine in pregnancy and lactation: a case report **Epilepsia** 38 (1997) 1039-1041.

TONG, X. e PATSALOS, P.N. - A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. **Br. J. Pharmacol.** 133 (2001) 867-874.

TORRA, M. [et al.] - Optimized procedure for lamotrigine analysis in serum by high-performance liquid chromatography without interferences from other frequently coadministered anticonvulsants. **Ther. Drug Monit.** 22 (2000) 621-625.

TRAN, T.A. [et al.] - Lamotrigine clearance during pregnancy. **Neurol.** 59 (2002) 251-255.

TSIROPOULOS, I. [et al.] - Saliva and serum concentration of lamotrigine in patients with epilepsy. **Ther. Drug Monit.** 22 (2000) 517-521.

TURAZZINI, M. [et al.] - Serum levels of carbamazepine and cortical excitability by magnetic brain stimulation. **Neurol. Sci.** 25 (2004) 83-90.

URE, J.A. e PERASSOLO, M. - Update on the pathophysiology of the epilepsies. **J. Neurol. Sci.** 177 (2000) 1-17.

VAUZELLE-KERVROEDAN, F. [et al.] - Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. **Br. J. Clin. Pharmacol.** 41 (1996) 325-330.

VEGGIOTTI, P. [et al.] - Lamotrigine in infantile spasms **Lancet** 344 (1994) 1375-1376.

VELEZ, A. e ESLAVA-COBOS, J. - Epilepsy in Colombia: epidemiologic profile and classification of epileptic seizures and syndromes. **Epilepsia** 47 (2006) 193-201.

VESSMAN, J. - Selectivity or specificity? Validation of analytical methods from the perspective of an analytical chemist in the pharmaceutical industry. **J. Pharm. Biomed. Anal.** 14 (1996) 867-869.

VIDAL, E. [et al.] - Determination of lamotrigine in human serum by liquid chromatography. **J. Chromatogr. B** 736 (1999) 295-298.

VIEIRA, S.C. [et al.] - First unprovoked seizure: clinical and electrographic aspects. **J. Epilepsy Clin. Neurophysiol.** 12 (2006) 69-72.

VINIK, A. - Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. **J. Clin. Endocrinol. Metab.** 90 (2005) 4936-4945.

WALDMEIER, P.C. [et al.] - Similar potency of carbamazepine and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. **Neurol.** 45 (1995) 1907-1913.

WALKER, M.C. [et al.] - Microdialysis study of the neuropharmacokinetics of phenytoin in rat hippocampus and frontal cortex. **Epilepsia** 37 (1996) 421-427.

WALKER, M.C. [et al.] - Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. **Br. J. Pharmacol.** 130 (2000) 242-248.



WALTON, N.Y. [et al.] - Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model **Epilepsy Res.** 24 (1996) 19-28.

WANG, X. [et al.] - The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus) **Seizure** 13 (2004) 574-581.

WANG-TILZ, Y. [et al.] - Changes of seizure activity during rapid withdrawal of lamotrigine. **Eur. J. Neurol.** 12 (2005) 280-288.

WANG-TILZ, Y. [et al.] - Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy. **Epilepsia** 47 (2006) 233-239.

WARNER, A. [et al.] - Standards of laboratory practice: antiepileptic drug monitoring. **Clin. Chem.** 44 (1998) 1085-1095.

WEINTRAUB, D. [et al.] - Effect of antiepileptic drug comedication on lamotrigine clearance. **Arch. Neurol.** 62 (2005) 1432-1436.

WHITE, H.S. - Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. **Epilepsia** 38 (1997) S9-S17.

WHITE, H.S. - Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. **Epilepsia** 40 (1999) S2-S10.

WHO - World Health Organization Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report. WHO Technical Report Series. Geneva. 1992.

WIELING, J. [et al.] - Rational experimental design for bioanalytical methods validation: illustration using an assay method for total captopril in plasma. **J. Chromatogr. A** 730 (1996) 381-394.

WIESHMANN, U.C. - Clinical application of neuroimaging in epilepsy. **J. Neurol. Neurosurg. Psychiatry** 74 (2003) 466-470.

WILBUR, K. e ENSOM, M.H.H. - Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. **Clin. Pharmacokinet.** 38 (2000) 355-365.

WILLIAMS, J. [et al.] - Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. **Epilepsia** 44 (2003) 40-45.

WILLIAMS, J. [et al.] - Self-discontinuation of antiepileptic medication in pregnancy: detection by hair analysis. **Epilepsia** 43 (2002) 824-831.

WILLMORE, L.J. - Choice and use of newer anticonvulsant drugs in older patients. **Drugs Aging** 17 (2000) 441-452.

WILSON, C.L. - Intracranial electrophysiological investigation of the human brain in patients with epilepsy: contributions to basic and clinical research. **Exp. Neurol.** 187 (2004) 240-245.

WNUK, W. [et al.] - Topiramate decreases lamotrigine concentrations. **Ther. Drug Monit.** 21 (1999) 449.

WONG, G. [et al.] - Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. **Epilepsia** 42 (2001) 237-244.

WONG, I.C.K. [et al.] - Factors influencing the incidence of lamotrigine-related skin rash. **Ann. Pharmacother.** 33 (1999) 1037-1042.

WOOTTON, R. [et al.] - Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. **Br. J. Clin. Pharmacol.** 43 (1997) 23-27.

YALÇIN, B. e KARADUMAN, A. - Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid **J. Am. Acad. Dermatol.** 43 (2000) 898-899.

YAMASHITA, S. [et al.] - Simple and rapid analysis of lamotrigine, a novel antiepileptic, in human serum by high-performance liquid chromatography using a solid-phase extraction technique. **J. Chromatogr. B** 670 (1995) 354-357.

YEN, D. [et al.] - Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring. **Epilepsia** 42 (2001) 251-255.

YOUSSEF, N.F. e TAHA, E.A. - Development and validation of spectrophotometric, TLC and HPLC methods for the determination of lamotrigine in presence of its impurity. **Chem. Pharm. Bull.** 55 (2007) 541-545.

YUEN, A.W.C. [et al.] - Sodium valproate acutely inhibits lamotrigine metabolism. **Br. J. Clin. Pharmacol.** 33 (1992) 511-513.

YUEN, W.C. e PECK, A.W. - Lamotrigine pharmacokinetics: oral and i.v. infusion in man. **Br. J. Clin. Pharmacol.** 26 (1988) 242P.

YUKAWA, E. - Optimization of antiepileptic drug therapy: the importance of serum drug concentration monitoring. **Clin. Pharmacokinet.** 31 (1996) 120-130.

ZHOU, D. [et al.] - Influence on ictal seizure semiology of rapid withdrawal of carbamazepine and valpoate in monotherapy. **Epilepsia** 43 (2002a) 386-393.

ZHOU, D. [et al.] - Influence on ictal seizure semiology of rapid withdrawal of lamotrigine and carbamazepine. **Epilepsia** 43 (supp. 7) (2002b) 298.

ZHOU, M. [et al.] - Determination of vertilmicin in rat serum by high-performance liquid chromatography using 1-fluoro-2,4-dinitrobenzene derivatization. **J. Chromatogr. B** 798 (2003) 43-48.

ZONA, C. [et al.] - Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine. **Epilepsia** 43 (2002) 685-690.